Teresa Pollicino

Qualifica:
Professori Associati
SSD:
MED/04
Telefono:
090 2212273
Fax:
090 2213594
Email:
Struttura di appartenenza:

Elenco insegnamenti per l'anno accademico 2016/2017

Denominazione Insegnamento Corso di Studi Percorso
DIAGNOSTICA MOLECOLARE MICROBIOLOGICABIOTECNOLOGIE PER LA SALUTEDIAGNOSTICO-MOLECOLARE MEDICO
ESAME TEORICO PRATICO I ANNOMEDICINA INTERNAcomune
ESAME TEORICO PRATICO I ANNOMEDICINA INTERNAcomune
FISIOPATOLOGIAORTOTTICA ED ASSISTENZA OFTALMOLOGICAcomune
PATOLOGIA GENERALEODONTOIATRIA E PROTESI DENTARIAcomune

Elenco insegnamenti per l'anno accademico 2015/2016

Denominazione Insegnamento Corso di Studi Percorso
ESAME TEORICO PRATICO I ANNOMEDICINA INTERNAcomune
ESAME TEORICO PRATICO I ANNOMEDICINA INTERNAcomune
MEDICINA DI LABORATORIO - MEDICINA E CHIRURGIAcomune
MEDICINA DI LABORATORIO - MEDICINA E CHIRURGIAcomune

Orario di Ricevimento

GiornoOra inizioOra fineLuogo
Giovedì 12:00 14:00Laboratorio di Biologia Molecolare Pad. C 2° Piano
Note: Previo contatto email (tpollicino@unime.it) o telefonico (090.2217070)è possibile incontrarsi dal lunedì al sabato ad un orario da concordare
Nata a Monforte S. Giorgio (ME) il 20 luglio 1964

Ha conseguito la specializzazione in Medicina Interna presso l’Università di Messina, in data 30 ottobre 2001, riportando la votazione di 50 su 50 e lode accademica.
Ha conseguito la specializzazione in Ematologia Generale presso l'Università di Messina, in data 28 ottobre 1994, riportando la votazione di 50 su 50 e lode accademica.
Ha conseguito la laurea in Medicina e Chirurgia presso l'Università di Messina, in data 10 luglio 1990, riportando la votazione di 110 su 110 e lode accademica.

Carriera accademica e professionale
Dal 2003 a tutt’oggi ricercatore universitario con nomina di professore aggregato, settore scientifico disciplinare MED46 (Scienze Tecniche di Medicina di Laboratorio) presso l’Università di Messina.
1998 - 2003 ricercatore universitario, settore scientifico disciplinare MED09 (Medicina Interna) presso l’Università di Messina.
Dal 1998 a tutt’oggi responsabile scientifico del Laboratorio di ricerca e diagnostica dell’Unità Operativa Complessa di Epatologia Clinica e Biomolecolare (direttore Prof. G. Raimondo) del Policlinico Universitario di Messina.

Borse di Studio ed Esperienze di Ricerca presso Istituzioni diverse da quelle di appartenenza

2002 - 2003 “visiting scientist” nel Laboratorio di Espressione Genica (direttore: Prof. M. Levrero) presso il Centro di Ricerca Sperimentale, Istituto Regina Elena di Roma.

1996 - 1998 “research fellow” nel laboratorio diretto dalla dott.ssa M.A. Buendia presso l'Unité de Recombinaison et Expression Génétique, Dipartement des Retrovirus, dell'Institut Pasteur di Parigi (direttore: Prof. P. Tiollais).

Nel 1998 “vacataire” per conto dell’"Institut National de la Santé et de la Recherche Médicale” (INSERM) Francese.

Nel 1997 vincitrice di una Borsa di Studio, messa a concorso dalla "Fondation pour la Recherche Medicale Francaise".

Maggio-luglio 1993, “visiting scientist” presso il Dipartimento di Virologia del "Heinrich-Pette-Institut" dell'Università di Amburgo, diretto dal Prof. H. Will

Nel 1992 vincitrice di una Borsa di Studio Formez messa a concorso dal Consorzio Mario Negri Sud, Santa Maria Imbaro (CH)

Da febbraio 1991 a luglio 1992 “research fellow” presso l'Unità di Immunoregolazione Molecolare del Laboratorio di Immunologia dell'Istituto Mario Negri di Milano, diretto dal prof. A. Mantovani

Nel 1991 vincitrice di una Borsa di Studio messa a concorso dalla Fondazione Bonino-Pulejo

Riconoscimenti
- “Prize for best oral presentation” 38th Annual Meeting of the European Association for the Study of the Liver. Geneva, Switzerland , July 3 – 6, 2003 per il lavoro scientifico “Class I Deacetylases Inhibitors Affect HBV Replication by Modulating the Acetylation Status of cccDNA-Bound H3 and H4 Histones”.

- Premio A.I.S.F.-FADE per la miglior pubblicazione scientifica italiana di epatologia pubblicata nel 2004: “Hepatitis B Virus Maintains its Pro-oncogenic Properties in the Case of Occult HBV Infection” [Pollicino T. et al. - Gastroenterology 2004;126:102–110].

Finanziamenti
Responsabile scientifico del progetti di ricerca:
- ” Analisi Molecolare di HBV isolati da soggetti vaccinati contro l’epatite B 15 -18 anni fa e che hanno sviluppato infezione da HBV” che nell’ambito dei Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN 2008) ha ottenuto un finanziamento di Euro 32.700.
- Studio dell'infezione occulta da virus dell'epatite B e di altri fattori potenzialmente implicati nell'evoluzione della malattia epatica da virus C e nella risposta al trattamento antivirale in una casistica della Sicilia Orientale e della Calabria” PRIN 2005, finanziamento di Euro 71.100.

Ha ottenuto finanziamenti per tutti i progetti di ricerca presentati annualmente, dall’entrata in ruolo quale Ricercatore Universitario nell’ambito dei “Progetti Ordinari di Ateneo” (PRA) messi a bando dall’Università di Messina.
Partecipa a numerosi progetti per i quali l’Unita di ricerca di appartenenza ha ricevuto finanziati da enti pubblici (CEE, FIRB, I.S.S, AIFA, MIUR) e privati (A.I.R.C., industrie)

Cariche istituzionali
Dal 2006 al 2009 è stata componente del Comitato Direttivo dell’Associazione Italiana per lo Studio del Fegato (AISF).
Dal 2009 è componente del Consiglio Direttivo della Fondazione Italiana per la Ricerca in Epatologia (FIRE).

Svolge attività di revisore scientifico per le seguenti riviste scientifiche internazionali: Gastroenterology, Hepatology, Journal of Hepatology, Journal of Medical Virology, Digestive and Liver Disease, Liver International, European Journal of Internal Medicine.

E’ stata organizzatrice scientifica dei seguenti meeting:
- “Malattia da virus dell’epatite B” corso di aggiornamento SIGE-AISF, 11-13 febbraio 2010, Chianciano
- “Management of HBV-related liver disease” 10th A.I.S.F. Pre-Meeting Course 20-22 febbraio 2008
- “Occult hepatitis B virus infection: biology and clinical impact” 7-8 marzo 2008, Taormina.
- “Workshop: Occult Hepadnavirus Infection” 19 settembre 2007, Roma (nel corso del 2007 International Meeting on Molecular Biology of hepatitis B Virus).
E’ stata speaker o moderatore in occasione di svariati meeting nazionali ed internazionali.

Attività Didattica
Università di Messina, Facoltà di Medicina e Chirurgia
Corso di Laurea in Medicina e Chirurgia :
- Insegnamento di Scienze Tecniche di Medicina e di Laboratorio (Corso Integrato di Medicina di Laboratorio)
- Insegnamento di Fisiopatologia (Corso Integrato di Fisiopatologia delle Malattie Umane)
Corso di Laurea in Biotecnologie
Indirizzo Medico
- Insegnamento di Scienze e Tecniche di Medicina e di Laboratorio (Corso Integrato di Diagnostica di Patologia d’Organo)
Indirizzo Biologico
- Insegnamento di Tecniche di Laboratorio
Corso di Laurea in Biotecnologie per la Salute
- Insegnamento di Diagnostica Molecolare Virologica
Scuole di Specializzazione
- Medicina Interna: Insegnamento di Patologia Molecolare
- Medicina Interna: Insegnamento di Genetica Medica
- Ematologia: Insegnamento di Patologia Molecolare
- Malattie Infettive: Insegnamento di Tecniche Immunologiche delle Malattie Infettive
- Scuola di Specializzazione in Allergologia e Immunologia: Insegnamento di Medicina di Laboratorio

Docente all’European Association for the Study of the Liver Basic School of Hepatology (“Corse 5. Hepatitis B and C: Molecular Virology and Antiviral Targets”; Lousanne, Switzerland; 25-27 February, 2010)


PUBLICATIONS (Total Impact Factor: 455)

1. NS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C.
Maimone S, Musolino C, Squadrito G, Raffa G, Pollicino T, Raimondo G.
Antivir Ther. 2013;18(1):131-4.

2. Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy.
Saitta C, Musolino C, Marabello G, Martino D, Leonardi MS, Pollicino T, Altavilla G, Raimondo G.
Dig Liver Dis. 2013 Mar 11. doi:pii: S1590-8658(13)00042-X. 10.1016/j.dld.2013.01.022.

3. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis.
Covolo L, Pollicino T, Raimondo G, Donato F.
Dig Liver Dis. 2013 Mar;45(3):238-44. doi: 10.1016/j.dld.2012.09.021.

4. Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma.
Pollicino T, Vegetti A, Saitta C, Ferrara F, Corradini E, Raffa G, Pietrangelo A, Raimondo G.
J Hepatol. 2013 Jan;58(1):190-3. doi: 10.1016/j.jhep.2012.09.005.

5. Occult hepatitis B virus infection.
Raimondo G, Caccamo G, Filomia R, Pollicino T.
Seminars in Immunopathology 2012, in press (IF: 5.2)

6. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels.
Pollicino T, Amaddeo G, Restuccia A, Raffa G, Alibrandi A, Cutroneo G, Favaloro A, Maimone S, Squadrito G, Raimondo G.
Hepatology 2012, in press (IF: 10.885)

7. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways.
Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D'Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M, Pediconi N.
Journal of Hepatology. 2011, in press (IF: 9.334)

8. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.
Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M.
Journal of Clinical Investigation. 2012;122:529-37. (IF: 14.152)

9. Hepatitis E virus infection as a cause of acute hepatitis in south Italy.
Cacciola I, Messineo F, Cacopardo B, Di Marco V, Galli C, Squadrito G, Musolino C, Saitta C, Pollicino T, Raimondo G.
Digestive and Liver Disease 2011;43:996-1000 (IF: 2.805)

10. Hepatocellular carcinoma: the point of view of the hepatitis B virus.
Pollicino T, Saitta C, Raimondo G.
Carcinogenesis. 2011; 32:1122-32. (IF: 5.402)

11. Occult hepatitis B virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C.
Raimondo G, Pollicino T, Levrero M, Craxì A. Hepatology. 2011;54:373. (IF: 10.885)

12. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses.
Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, Alibrandi A, Squadrito G, Cacciola I, Calvi C, Colucci G, Levrero M, Raimondo G.
Journal of Virology. 2011; 85:432-9. (IF: 5.189)

13. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody.
Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, Pollicino T, Li L, Kennedy PT, Lopatin U, Macary PA, Bertoletti A.
Journal of Virology 2011; 85:1935-42 (IF: 5.189)

14. Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop.
Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxì A, Filice G, Levrero M, Mazzotta F, Pastore G, Piccinino F, Prati D, Raimondo G, Sagnelli E, Toti M, Brunetto M, Bruno R, Di Marco V, Ferrari C, Gaeta GB, Lampertico P, Marzano A, Pollicino T, Puoti M, Santantonio T, Smedile A.
Digestive and Liver Disease. 2011;43:259-65 (IF: 2.805)

15. A 2010 update on occult hepatitis B infection.
Raimondo G, Pollicino T, Romanò L, Zanetti AR.
Pathol Biol . 2010;58:254-7. (IF: 0.848)

16. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases.
Prati D, Gasbarrini A, Mazzotta F, Sagnelli E, Carosi G, Abrescia N, Alberti A, Ambu S, Andreone P, Andriulli A, Angelico M, Antonucci GF, Ascione A, Belli LS, Bruno R, Bruno S, Burra P, Cammà C, Caporaso N, Cariti G, Cillo U, Coppola N, Craxì A, De Luca A, De Martin E, Di Marco V, Fagiuoli S, Ferrari C, Gaeta GB, Galli M, Grieco A, Grossi P, Licata A, Maida I, Mangia A, Marino N, Maserati R, Missale G, Mondelli M, Nasta P, Niro G, Persico M, Petrelli E, Picciotto A, Piscaglia F, Pollicino T, Prati D, Puoti C, Puoti M, Raimondo G, Rumi ...et al Digestive and Liver Disease 2010;42:81-91 (IF: 2.805)

17. Control of cccDNA function in hepatitis B virus infection.
Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M
Journal of Hepatology. 2009;51:581-92. (IF: 9.334)

18. Variability of reverse-transcriptase and overlapping s-gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients
Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, Squadrito G, Di Marco V, Craxì A, Raimondo G.
Antiviral Therapy, 2009;14:649-54 (IF: 3.774)

19. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.
Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M.
Proceedings of National Academy of Science U S A. 2009; 24;106(47):19975-9. (IF: 9.771)

20. Statements from the Taormina expert meeting on occult hepatitis B virus infection.
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F.
Journal of Hepatology, 2008; 49:652-7. (IF: 9.334)

21. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection.
Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G.
Gastroenterology. 2008;134:1470-1481. (IF: 12.032)

22. Occult hepatitis B virus in liver tissue of individuals without hepatic disease.
Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, Squadrito G, Pollicino T.
Journal of Hepatology, 2008; 48:743-746. (IF: 9.334)

23. Occult hepatitis B virus infection.
Raimondo G, Pollicino T, Cacciola I, Squadrito G.
Journal of Hepatology. 2007; 46:160-70 (IF: 9.334)

24. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma.
Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G.
Hepatology. 2007; 45:277-285 (IF: 10.885)

25. Is there a downgrading in the alert about the hepatitis B virus infection in Italy?
Raimondo G, Isgro G, Caccamo G, Pollicino T, Squadrito G and the Calabrian HBV Study Group.
Digestive and Liver Disease 2007; 39:257-61 (IF: 2.805)

26. Disease progression and liver cancer in the ferroportin disease.
Corradini E, Ferrara F, Pollicino T, Vegetti A, Abbati GL, Losi L, Raimondo G, Pietrangelo A.
Gut. 2007; 56:1030-2. (IF: 10.614)

27. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C.
Raffa G, Maimone S, Cargnel A, Santantonio T, Antonucci G, Massari M, Schiavini M, Caccamo G, Pollicino T, Raimondo G.
AIDS 2007; 21: 2171-2175 (IF: 6.348)

28. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.
Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzù D, Raimondo G.
Cancer, 2006; 106:1326-30. (IF: 5.131)

29. Hepatitis B Virus (HBV) replication is regulated by the acetylation status of HBV cccDNA-bound H3 and H4 histones.
Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Gastroenterology, 2006; 130:823-37. (IF: 12.032)

30. What is the clinical impact of occult hepatitis B virus infection?
Raimondo G., Pollicino T., Squadrito G.
Lancet, 2005, 365: 638-640 (IF: 33.633)

31. Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in one-year follow up study.
Cacciola I, Spatari G, Pollicino T, Costantino L, Zimbaro G, Brancatelli S, Fenga C, Caccamo G, Squadrito G, Raimondo G.
Liver International, 2005; 25:555-563. (IF: 3.840)

32. Hepatitis B Virus (HBV) maintains its pro-oncogenic properties in case of occult HBV infection
Pollicino T., Squadrito G., Cerenzia G., Cacciola I., Raffa G., Craxì A., Farinati F., Missale G., Smedile A., Tiribelli C., Villa E., Raimondo G.
Gastroenterology, 2004; 126: 102-110 (IF: 12.032)

33. Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases.
Raimondo G., Costantino L., Caccamo G., Pollicino T., Squadrito G., Cacciola I., Brancatelli S.
Journal of Hepatology, 2004, 40: 515-519. (IF: 9.334)

34. TT virus has a ubiquitous diffusion in human body tissues: analyses of paired serum and tissue samples.
Pollicino T, Raffa G, Squadrito G, Costantino L, Cacciola I, Brancatelli S, Alafaci C, Florio MG, Raimondo G.
Journal of Viral Hepatitis, 2003;10: 95-102. (IF: 3.502)

35. High prevalence of non-organ-specific autoantibodies in hepatitis C virus-infected cirrhotic patients from southern Italy.
Squadrito G, Previti M, Lenzi M, Le Rose EP, Caccamo G, Restuccia T, Di Cesare E, Pollicino T, Raimondo G.
Digestive Disease and Science, 2003; 48: 349-53. (IF: 2.060)

36. Clinical Virology of hepatitis B virus infection.
Raimondo G., Pollicino T., Squadrito G.
Journal of Hepatology, 2003, 39: S26-30. (IF: 9.334)

37. Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection.
Squadrito G, Orlando ME, Pollicino T, Raffa G, Restuccia T, Cacciola I, Brancatelli S, Di Marco V, Picciotto A, Colucci G, Craxì A, Raimondo G
American Journal of Gastroenterology, 2002; 97:1518-23. (IF: 6.882)

38. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver.
Terradillos O, de La Coste A, Pollicino T, Neuveut C, Sitterlin D, Lecoeur H, Gougeon ML, Kahn A, Buendia MA.
Oncogene, 2002;21:377-86. (IF: 7.414)

39. Genomic heterogeneity of Hepatitis B Virus (HBV) and outcome of perinatal HBV infection.
Cacciola I, Cerenzia G, Pollicino T, Squadrito G, Castellaneta S, Zanetti AR, Mieli-Vergani G, Raimondo G.
Journal of Hepatology 2002;36:426-32. (IF: 9.334)

40. Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?
Squadrito G, Raffa G, Restuccia T, Pollicino T, Brancatelli S, Raimondo G.
Journal of Viral Hepatitis, 2002; 9: 360-9. (IF: 3.502)

41. Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses.
Schuster R, Hildt E, Chang SF, Terradillos O, Pollicino T, Lanford R, Gerlich WH, Will H, Schaefer S.
Oncogene. 2002; 21: 6606-13. (IF: 7.414)

42. Analysis of Haemochromatosis gene mutations in a population from the Mediterranean Basin.
Campo S, Restuccia T, Villari D, Raffa G, Cucinotta D, Squadrito G, PollicinoT, Raimondo G.
Liver, 2001; 21: 233-6. (IF: 3.840)

43. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection.
Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Villari D, de Franchis R, Santantonio T, Brancatelli S, Colucci G, Raimondo G.
Hepatology, 2000; 31: 507-512. (IF: 10.885)

44. Occult hepatitis B virus infection.
Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, Mondelli M, Pollicino T, Squadrito G, Tiribelli C.
Digestive and Liver Disease, 2000;32:822-6. (IF: 2.805)

45. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G.
The New England Journal of Medicine, 1999; 341: 22-26. 29 (IF: 53.484)

46. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro.
Terradillos O, Pollicino T, Lecoeur H, Tripodi M, Gougeon ML, Tiollais P, Buendia MA.
Oncogene, 1998; 17 (16): 2115-23. (IF: 7.414)

47. Pro-apoptotic effect of the hepatitis B virus X gene.
Pollicino T, Terradillos O, Lecoeur H, Gougeon ML, Buendia MA.
Biomed & Pharmacother, 1998; 52: 363-8. (IF: 2.208)

48. Outcome of liver disease and response to interferon treatment are not influenced by Hepatitis B virus core gene variability in children with chronic type B Hepatitis.
Schepis F, Verucchi G, Pollicino T, Attard L, Brancatelli S, Longo G, Raimondo G.
Journal of Hepatology, 1997, 26: 765-770. (IF: 9.334)

49. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis.
Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, Sagliocca L, Pasquali M, Tanzi E, Longo G, Raimondo G.
Hepatology, 1997; 26: 495-499. (IF: 10.885)

50. Evaluation of hepatitis B and C virus infections in patients with non-Hodgkin’s lymphoma and without liver disease.
Musolino C, Campo S, Pollicino T, Squadrito G, Spatari G, Raimondo G. Haematologica, 1996, 81: 162-164. (IF: 6.532)

51. Severe outcome of hepatitis B virus (HBV) infection and lack of HBV e antigen-defective virus emergence in patients homozygous for HLA class I alleles.
Pollicino T, Pernice F, Campo S, Mesiti O, Misefari V, Pernice M, Raimondo G.
Journal of General Virology, 1996, 77: 1833-1836. (IF: 3.568)

52. Hepatitis B e antigen detection in formalin fixed liver biopsy specimens: a tool to investigate wild-type and e-minus variant HBV infection.
Villari D, Pollicino T, Spinella S, Russo F, Campo S, Rodinò G, Squadrito G, Longo G, Raimondo G.
American Journal of Clinical Pathology, 1995, 103: 136-140. (IF: 2.504)

53. Pre-S and core gene heterogeneity in hepatitis B virus (HBV) genomes isolated from patients with long-lasting HBV infection.
Pollicino T, Campo S, Raimondo G.
Virology, 1995, 208, 672-677. (IF: 3.305)

54. Heterogeneity of HBV genome.
Raimondo G, Pollicino T, Campo S, Squadrito G.
Italian Journal of Gastroenterology (Lectures on Viruses of Hepatitis),1995, 27, 88-90. (IF: 2.805)

55. Type II Interleukin-1 receptor is not expressed in cultered endothelial cells and is not involved in endothelial cell activation.
Colotta F, Sironi M, Borrè A, Pollicino T, Bernasconi S, Boraschi D, Mantovani A. Blood, 1993, 81: 1347-1351 (IF: 10.558)

56. Divergent effects of interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells.
Sironi M, Munoz C, Pollicino T, Siboni A, Sciacca FL, Bernasconi S, Vecchi A, Colotta F, Mantovani A.
European Journal of Immunology, 1993, 23: 2692-2695. (IF: 4.942)

57. Regulated expression of vascular cell adhesion molecule-1 in human malignant melanoma.
Jonjic N, Martin-Padura I, Pollicino T, Bernasconi S, Jilek P, Bigotti A, Artarini R, Anichini A, Parmiani G, Colotta F, Dejana E, Mantovani A, Natali PG.
American Journal of Pathology, 1992, 141: 1323-1330. (IF: 5.224)
Birth: July 20, 1964, Monforte S. Giorgio (Messina), Italy

Education
2001 Board certified in Internal Medicine, University of Messina, Italy 50/50 cum laude
1994 Board certified in Haematology, University of Messina, Italy 50/50 cum laude
1990 M.D. in Medicine and Surgery, University of Messina, Italy 110/110 cum laude
Research and professional experience
1998-present Assistant professor (MED46), University of Messina, Italy
1996-98 Postdoctoral fellow, Research fellow at the “Unité de Recombinaison et
Expression Génétique – Department de Retrovirus” Institut Pasteur, Paris, France.
1994-96 Postdoctoral fellow, Laboratory of Molecular Biology, Department of
Internal Medicine, University of Messina, Italy.
1991-94 Residency at the Department of Internal Medicine, University of Messina, Italy
May1993/July’ 93 Visiting scientist, Department of Virology, “Heinrich-Pette-Institut”, Hamburg University, Germany
1991-92 Postdoctoral fellow, Laboratory of Molecular Biology, “M. Negri” Institute Milan, Italy

Fellowships and prizes

- 1991: one year fellowship from “Fondazione Bonino-Pulejo” Messina, Italy

- 1992: two years fellowship from “Consorzio Mario Negri Sud”, Santa Maria Imbaro (CH), Italy

- 1997: one year fellowship from "Fondation pour la Recherche Medicale Francaise" Paris, France.

- 1998 “Vacataire”, ”Institut National de la Santé et de la Recherche Médicale” (INSERM) Institut Pasteur, Paris, France.
- 2003 “Prize for best oral presentation”, 38th Annual Meeting of the European Association for the Study of the Liver. Geneva, Switzerland , July 3 – 6, 2003 for the study “Class I Deacetylases Inhibitors Affect HBV Replication by Modulating the Acetylation Status of cccDNA-Bound H3 and H4 Histones”.
- A.I.S.F.-FADE for the best 2004 Italian publication in hepatology [Pollicino T. et al. - Gastroenterology 2004;126:102–110].

PUBLICATIONS (Total Impact Factor: 445,686)

1. Occult hepatitis B virus infection.
Raimondo G, Caccamo G, Filomia R, Pollicino T.
Seminars in Immunopathology 2012, in press (IF: 5.2)

2. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels.
Pollicino T, Amaddeo G, Restuccia A, Raffa G, Alibrandi A, Cutroneo G, Favaloro A, Maimone S, Squadrito G, Raimondo G.
Hepatology 2012, in press (IF: 10.885)

3. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways.
Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D'Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M, Pediconi N.
Journal of Hepatology. 2011, in press (IF: 9.334)

4. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.
Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M.
Journal of Clinical Investigation. 2012;122:529-37. (IF: 14.152)

5. Hepatitis E virus infection as a cause of acute hepatitis in south Italy.
Cacciola I, Messineo F, Cacopardo B, Di Marco V, Galli C, Squadrito G, Musolino C, Saitta C, Pollicino T, Raimondo G.
Digestive and Liver Disease 2011;43:996-1000 (IF: 2.805)

6. Hepatocellular carcinoma: the point of view of the hepatitis B virus.
Pollicino T, Saitta C, Raimondo G.
Carcinogenesis. 2011; 32:1122-32. (IF: 5.402)

7. Occult hepatitis B virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C.
Raimondo G, Pollicino T, Levrero M, Craxì A. Hepatology. 2011;54:373. (IF: 10.885)

8. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses.
Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, Alibrandi A, Squadrito G, Cacciola I, Calvi C, Colucci G, Levrero M, Raimondo G.
Journal of Virology. 2011; 85:432-9. (IF: 5.189)

9. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody.
Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, Pollicino T, Li L, Kennedy PT, Lopatin U, Macary PA, Bertoletti A.
Journal of Virology 2011; 85:1935-42 (IF: 5.189)

10. Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop.
Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxì A, Filice G, Levrero M, Mazzotta F, Pastore G, Piccinino F, Prati D, Raimondo G, Sagnelli E, Toti M, Brunetto M, Bruno R, Di Marco V, Ferrari C, Gaeta GB, Lampertico P, Marzano A, Pollicino T, Puoti M, Santantonio T, Smedile A.
Digestive and Liver Disease. 2011;43:259-65 (IF: 2.805)

11. A 2010 update on occult hepatitis B infection.
Raimondo G, Pollicino T, Romanò L, Zanetti AR.
Pathol Biol . 2010;58:254-7. (IF: 0.848)

12. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases.
Prati D, Gasbarrini A, Mazzotta F, Sagnelli E, Carosi G, Abrescia N, Alberti A, Ambu S, Andreone P, Andriulli A, Angelico M, Antonucci GF, Ascione A, Belli LS, Bruno R, Bruno S, Burra P, Cammà C, Caporaso N, Cariti G, Cillo U, Coppola N, Craxì A, De Luca A, De Martin E, Di Marco V, Fagiuoli S, Ferrari C, Gaeta GB, Galli M, Grieco A, Grossi P, Licata A, Maida I, Mangia A, Marino N, Maserati R, Missale G, Mondelli M, Nasta P, Niro G, Persico M, Petrelli E, Picciotto A, Piscaglia F, Pollicino T, Prati D, Puoti C, Puoti M, Raimondo G, Rumi ...et al Digestive and Liver Disease 2010;42:81-91 (IF: 2.805)

13. Control of cccDNA function in hepatitis B virus infection.
Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M
Journal of Hepatology. 2009;51:581-92. (IF: 9.334)

14. Variability of reverse-transcriptase and overlapping s-gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients
Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, Squadrito G, Di Marco V, Craxì A, Raimondo G.
Antiviral Therapy, 2009;14:649-54 (IF: 3.774)

15. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.
Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M.
Proceedings of National Academy of Science U S A. 2009; 24;106(47):19975-9. (IF: 9.771)

16. Statements from the Taormina expert meeting on occult hepatitis B virus infection.
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F.
Journal of Hepatology, 2008; 49:652-7. (IF: 9.334)

17. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection.
Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G.
Gastroenterology. 2008;134:1470-1481. (IF: 12.032)

18. Occult hepatitis B virus in liver tissue of individuals without hepatic disease.
Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, Squadrito G, Pollicino T.
Journal of Hepatology, 2008; 48:743-746. (IF: 9.334)

19. Occult hepatitis B virus infection.
Raimondo G, Pollicino T, Cacciola I, Squadrito G.
Journal of Hepatology. 2007; 46:160-70 (IF: 9.334)

20. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma.
Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G.
Hepatology. 2007; 45:277-285 (IF: 10.885)

21. Is there a downgrading in the alert about the hepatitis B virus infection in Italy?
Raimondo G, Isgro G, Caccamo G, Pollicino T, Squadrito G and the Calabrian HBV Study Group.
Digestive and Liver Disease 2007; 39:257-61 (IF: 2.805)

22. Disease progression and liver cancer in the ferroportin disease.
Corradini E, Ferrara F, Pollicino T, Vegetti A, Abbati GL, Losi L, Raimondo G, Pietrangelo A.
Gut. 2007; 56:1030-2. (IF: 10.614)

23. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C.
Raffa G, Maimone S, Cargnel A, Santantonio T, Antonucci G, Massari M, Schiavini M, Caccamo G, Pollicino T, Raimondo G.
AIDS 2007; 21: 2171-2175 (IF: 6.348)

24. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.
Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzù D, Raimondo G.
Cancer, 2006; 106:1326-30. (IF: 5.131)

25. Hepatitis B Virus (HBV) replication is regulated by the acetylation status of HBV cccDNA-bound H3 and H4 histones.
Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Gastroenterology, 2006; 130:823-37. (IF: 12.032)

26. What is the clinical impact of occult hepatitis B virus infection?
Raimondo G., Pollicino T., Squadrito G.
Lancet, 2005, 365: 638-640 (IF: 33.633)

27. Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in one-year follow up study.
Cacciola I, Spatari G, Pollicino T, Costantino L, Zimbaro G, Brancatelli S, Fenga C, Caccamo G, Squadrito G, Raimondo G.
Liver International, 2005; 25:555-563. (IF: 3.840)

28. Hepatitis B Virus (HBV) maintains its pro-oncogenic properties in case of occult HBV infection
Pollicino T., Squadrito G., Cerenzia G., Cacciola I., Raffa G., Craxì A., Farinati F., Missale G., Smedile A., Tiribelli C., Villa E., Raimondo G.
Gastroenterology, 2004; 126: 102-110 (IF: 12.032)

29. Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases.
Raimondo G., Costantino L., Caccamo G., Pollicino T., Squadrito G., Cacciola I., Brancatelli S.
Journal of Hepatology, 2004, 40: 515-519. (IF: 9.334)

30. TT virus has a ubiquitous diffusion in human body tissues: analyses of paired serum and tissue samples.
Pollicino T, Raffa G, Squadrito G, Costantino L, Cacciola I, Brancatelli S, Alafaci C, Florio MG, Raimondo G.
Journal of Viral Hepatitis, 2003;10: 95-102. (IF: 3.502)

31. High prevalence of non-organ-specific autoantibodies in hepatitis C virus-infected cirrhotic patients from southern Italy.
Squadrito G, Previti M, Lenzi M, Le Rose EP, Caccamo G, Restuccia T, Di Cesare E, Pollicino T, Raimondo G.
Digestive Disease and Science, 2003; 48: 349-53. (IF: 2.060)

32. Clinical Virology of hepatitis B virus infection.
Raimondo G., Pollicino T., Squadrito G.
Journal of Hepatology, 2003, 39: S26-30. (IF: 9.334)

33. Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection.
Squadrito G, Orlando ME, Pollicino T, Raffa G, Restuccia T, Cacciola I, Brancatelli S, Di Marco V, Picciotto A, Colucci G, Craxì A, Raimondo G
American Journal of Gastroenterology, 2002; 97:1518-23. (IF: 6.882)

34. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver.
Terradillos O, de La Coste A, Pollicino T, Neuveut C, Sitterlin D, Lecoeur H, Gougeon ML, Kahn A, Buendia MA.
Oncogene, 2002;21:377-86. (IF: 7.414)

35. Genomic heterogeneity of Hepatitis B Virus (HBV) and outcome of perinatal HBV infection.
Cacciola I, Cerenzia G, Pollicino T, Squadrito G, Castellaneta S, Zanetti AR, Mieli-Vergani G, Raimondo G.
Journal of Hepatology 2002;36:426-32. (IF: 9.334)

36. Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?
Squadrito G, Raffa G, Restuccia T, Pollicino T, Brancatelli S, Raimondo G.
Journal of Viral Hepatitis, 2002; 9: 360-9. (IF: 3.502)

37. Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses.
Schuster R, Hildt E, Chang SF, Terradillos O, Pollicino T, Lanford R, Gerlich WH, Will H, Schaefer S.
Oncogene. 2002; 21: 6606-13. (IF: 7.414)

38. Analysis of Haemochromatosis gene mutations in a population from the Mediterranean Basin.
Campo S, Restuccia T, Villari D, Raffa G, Cucinotta D, Squadrito G, PollicinoT, Raimondo G.
Liver, 2001; 21: 233-6. (IF: 3.840)

39. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection.
Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Villari D, de Franchis R, Santantonio T, Brancatelli S, Colucci G, Raimondo G.
Hepatology, 2000; 31: 507-512. (IF: 10.885)

40. Occult hepatitis B virus infection.
Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, Mondelli M, Pollicino T, Squadrito G, Tiribelli C.
Digestive and Liver Disease, 2000;32:822-6. (IF: 2.805)

41. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G.
The New England Journal of Medicine, 1999; 341: 22-26. 29 (IF: 53.484)

42. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro.
Terradillos O, Pollicino T, Lecoeur H, Tripodi M, Gougeon ML, Tiollais P, Buendia MA.
Oncogene, 1998; 17 (16): 2115-23. (IF: 7.414)

43. Pro-apoptotic effect of the hepatitis B virus X gene.
Pollicino T, Terradillos O, Lecoeur H, Gougeon ML, Buendia MA.
Biomed & Pharmacother, 1998; 52: 363-8. (IF: 2.208)

44. Outcome of liver disease and response to interferon treatment are not influenced by Hepatitis B virus core gene variability in children with chronic type B Hepatitis.
Schepis F, Verucchi G, Pollicino T, Attard L, Brancatelli S, Longo G, Raimondo G.
Journal of Hepatology, 1997, 26: 765-770. (IF: 9.334)

45. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis.
Pollicino T, Zanetti AR, Cacciola I, Petit MA, Smedile A, Campo S, Sagliocca L, Pasquali M, Tanzi E, Longo G, Raimondo G.
Hepatology, 1997; 26: 495-499. (IF: 10.885)

46. Evaluation of hepatitis B and C virus infections in patients with non-Hodgkin’s lymphoma and without liver disease.
Musolino C, Campo S, Pollicino T, Squadrito G, Spatari G, Raimondo G. Haematologica, 1996, 81: 162-164. (IF: 6.532)

47. Severe outcome of hepatitis B virus (HBV) infection and lack of HBV e antigen-defective virus emergence in patients homozygous for HLA class I alleles.
Pollicino T, Pernice F, Campo S, Mesiti O, Misefari V, Pernice M, Raimondo G.
Journal of General Virology, 1996, 77: 1833-1836. (IF: 3.568)

48. Hepatitis B e antigen detection in formalin fixed liver biopsy specimens: a tool to investigate wild-type and e-minus variant HBV infection.
Villari D, Pollicino T, Spinella S, Russo F, Campo S, Rodinò G, Squadrito G, Longo G, Raimondo G.
American Journal of Clinical Pathology, 1995, 103: 136-140. (IF: 2.504)

49. Pre-S and core gene heterogeneity in hepatitis B virus (HBV) genomes isolated from patients with long-lasting HBV infection.
Pollicino T, Campo S, Raimondo G.
Virology, 1995, 208, 672-677. (IF: 3.305)

50. Heterogeneity of HBV genome.
Raimondo G, Pollicino T, Campo S, Squadrito G.
Italian Journal of Gastroenterology (Lectures on Viruses of Hepatitis),1995, 27, 88-90. (IF: 2.805)

51. Type II Interleukin-1 receptor is not expressed in cultered endothelial cells and is not involved in endothelial cell activation.
Colotta F, Sironi M, Borrè A, Pollicino T, Bernasconi S, Boraschi D, Mantovani A. Blood, 1993, 81: 1347-1351 (IF: 10.558)

52. Divergent effects of interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells.
Sironi M, Munoz C, Pollicino T, Siboni A, Sciacca FL, Bernasconi S, Vecchi A, Colotta F, Mantovani A.
European Journal of Immunology, 1993, 23: 2692-2695. (IF: 4.942)

53. Regulated expression of vascular cell adhesion molecule-1 in human malignant melanoma.
Jonjic N, Martin-Padura I, Pollicino T, Bernasconi S, Jilek P, Bigotti A, Artarini R, Anichini A, Parmiani G, Colotta F, Dejana E, Mantovani A, Natali PG.
American Journal of Pathology, 1992, 141: 1323-1330. (IF: 5.224)
* Afferenze, qualifiche prelevate dal Database CSA » Carriere del Personale
» Inserisci Curriculum


Ultimo aggiornamento: 21/04/2018

Università degli Studi di Messina - Piazza Pugliatti, 1 - 98122 Messina - tel. +39 090 6761
Cod. Fiscale 80004070837 - P.IVA 00724160833